Runfeng Zhang, Hong Yu, Miao Chen, Xiaoqi Qin, Jie Xiao, Yun Leng et al. A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. // British Journal of Haematology. – 2026. – DOI: 10.1111/bjh.70806. – URL: https://onlinelibrary.wiley.com/doi/10.1111/bjh.70806?af=R
Runfeng Zhang, Hong Yu, Miao Chen, Xiaoqi Qin, Jie Xiao, Yun Leng, Mingzhe Zhao, Jie Yu, Chunjie Qin, Xiuju Wang, Jingcheng Zhang, Wei Wang, Wenming Chen, Yanping Ma, Rong Fu, & Junling Zhuang (2026). A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/bjh.70806
Runfeng Zhang, et al. “A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.” British Journal of Haematology, 2026. doi:10.1111/bjh.70806.
@article{Zhang2026,
title = {A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma},
author = {Zhang, Runfeng and Yu, Hong and Chen, Miao and Qin, Xiaoqi and Xiao, Jie and Leng, Yun and Zhao, Mingzhe and Yu, Jie and Qin, Chunjie and Wang, Xiuju and Zhang, Jingcheng and Wang, Wei and Chen, Wenming and Ma, Yanping and Fu, Rong and Zhuang, Junling},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70806},
url = {https://onlinelibrary.wiley.com/doi/10.1111/bjh.70806?af=R}
}